Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience.

Background: Atezolizumab plus bevacizumab (A/B) received FDA approval as the first-line therapy for patients with advanced hepatocellular carcinoma (HCC) in 2020. However, optimal subsequent treatment options are unclear. Here, we describe clinical outcomes of advanced HCC patients following first-line treatment with A/B.

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.

Background: Breast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to ICIs, including in these "cold tumors". In clinical practice, when tTMB is not available, blood-based TMB score (bTMB) can be used to consider treatment with ICIs.

A rare case of traumatic reticulopericarditis in camel ().

Background: Traumatic reticulopericarditis (TRP) is rarely reported in camels. This report provides TRP in camels.

Case Description: She-camel (3 years old) with a history of anorexia, and stinky smell-bloody diarrhea for more than 3 weeks associated with pain, ventral thoracoabdominal edema, positive for metal detection examination that raised the suspicion of TRP.